This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Brandon Willis: Inventor in Biopharmaceutical Research
Introduction
Brandon Willis is an inventor based in Waltham, Massachusetts, and is associated with AstraZeneca AB. His patent work concerns potential therapeutic approaches for B-cell malignancies.
Latest Patents
Willis is named on 1 patent: “Therapeutic Combinations of Acalabrutinib and Capivasertib to Treat B-Cell Malignancies.” The disclosure describes combining acalabrutinib and capivasertib, or their pharmaceutically acceptable salts, to treat, prevent, or alleviate B-cell malignancies, including non-Hodgkin lymphoma. It also describes pharmaceutical compositions and kits containing the two medicines.
Career Highlights
The patent reflects work on combination therapies and pharmaceutical products intended for people with B-cell malignancies. Willis is associated with AstraZeneca AB, a biopharmaceutical company.
Collaborations
Hannah Dry and Andrew Bloecher are identified as Willis’s coworkers. Their names are associated with the collaborative context of his patent work.
Conclusion
Brandon Willis’s patent activity centers on a proposed acalabrutinib and capivasertib combination for B-cell malignancies, alongside related pharmaceutical compositions and kits.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile